Merck and Instituto Butantan announce collaboration to develop vaccines against dengue
Merck and Instituto Butantan announced a collaboration agreement to develop vaccines to protect against dengue virus disease, the mosquito-borne infection. Instituto Butantan and Merck have licensed certain rights from NIAID, for development of live attenuated tetravalent vaccines. December 12, 2018